Home Category Region Publishers About Us Contact Us
Japanese Korean Chinese
Home > Market Research Report > Medical Device > Catheter Equipment > Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017
Category
Medical Device (4395)
Cardiovascular Device (252)
Catheter Equipment (206)
CT and MRI and X ray (146)
Dental Equipment (177)
Disposable Medical Device (83)
Endoscopy Equipment (114)
Healthcare IT (310)
In Vitro Diagnostics Equipment (435)
Medical Imaging (425)
Molecular Imaging/Agents (29)
Nuclear Medical (76)
Ophthalmic Equipment (105)
Orthopedic (343)
Patient Monitoring (384)
Ultra Sound (50)
Wound Care (120)
Market Research Report

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017

Published by MedMarket Diligence
Published May, 2009 Product code 84696
Content info 290 pages, 61 Exhibits, 76 Company Profiles
Price
US $ 1950 Hard Copy
US $ 1950 PDF by E-mail (Single User License)
US $ 2150 PDF by E-mail (Single User License) & Hard Copy
US $ 3450 PDF by E-mail ( Site License)
US $ 4450 PDF by E-mail (Global Site License)


Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017 published by MedMarket Diligence in May, 2009. This report consists of 290 pages, 61 Exhibits, 76 Company Profiles and the price starts from US $ 1950.

Introduction

Abstract

This report details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

Methodology

MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources (annual reports, SEC 10K reports, company literature, others) on products and technologies on the market and under development. Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data (third party reports, brokerage reports, federal/state/international datasets) are used to corroborate and support assessments and projections. Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

Table of Contents

EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND

  • 1.1 Cardiovascular Disorders Applicable for Stent Implantation
    • 1.1.1 Acute Closure
    • 1.1.2 Restenosis After Angioplasty
  • 1.2 Risk Factors for Coronary Heart Disease
  • 1.3 Stenting vs. CABG and Angioplasty
  • 1.4 Alternative Therapies for Coronary Atherosclerosis
    • 1.4.1 Angioplasty With or Without Stenting
    • 1.4.2 Atherectomy
    • 1.4.3 Coronary Artery Bypass Graft (CABG)
      • 1.4.3.1 Open CABG
      • 1.4.3.2 Off-Pump Coronary Artery Bypass (OPCAB)
      • 1.4.3.3 MIDCAB (Minimally Invasive Direct Coronary Bypass)
      • 1.4.3.4 RACAB (Robotic Assisted Coronary Artery Bypass)
      • 1.4.3.5 Other Forms of CABG
    • 1.4.4 Transmyocardial Laser Revascularization (TMR)
    • 1.4.5 Genetic Therapies
    • 1.4.6 HDL Therapy
    • 1.4.7 Drug-Eluting Balloons
    • 1.4.8 Nanoparticles and Other Agents
  • 1.5 Incidence and Prevalence of Cardiovascular Stenting Procedures
  • 1.6 Complications Related to Cardiovascular Stents

SECTION 2: PRODUCTS, TECHNOLOGIES

  • 2.1 Materials Used in Cardiovascular Stents
  • 2.2 Various Stent Shapes and Resulting Impact
  • 2.3 FDA Approval of Cardiovascular Stents
  • 2.4 Reimbursement of Drug-Eluting Stents
  • 2.5 Bare Metal Stents
  • 2.6 Drug-Eluting Stents
    • 2.6.1 Abbott Vascular
    • 2.6.2 Boston Scientific
    • 2.6.3 Johnson & Johnson/Cordis
    • 2.6.4 Medtronic
    • 2.6.5 Other Drug-Eluting Stent Companies
  • 2.7 Bioabsorbable Stents
  • 2.8 Other Types of Stents
  • 2.9 Legal Proceedings
  • 2.10 Key Clinical Trials
    • 2.10.1 HORIZONS AMI
    • 2.10.2 SYNTAX
    • 2.10.3 SPIRIT
    • 2.10.4 COURAGE
    • 2.10.5 PROTECT
    • 2.10.6 ENDEAVOR
    • 2.10.7 FAME
    • 2.10.8 SORT OUT III
    • 2.10.9 DAPT
    • 2.10.10 ZEST

SECTION 3: MARKETS FORECASTS AND COMPETITOR SHARES

  • 3.1 Worldwide Market for Coronary Stents
    • 3.1.1 Worldwide Market for Drug-Eluting Coronary Stents
    • 3.1.2 Worldwide Market for Bare Metal Coronary Stents
    • 3.1.3 Worldwide Market for Absorbable Coronary Stents
  • 3.2 U.S. Market for Coronary Stents
    • 3.2.1 U.S. Market for Drug-Eluting Coronary Stents
    • 3.2.2 U.S. Market for Bare Metal Coronary Stents
    • 3.2.3 U.S. Market for Absorbable Coronary Stents
  • 3.3 European Market for Coronary Stents
    • 3.3.1 European Market for Drug-Eluting Coronary Stents
    • 3.3.2 European Market for Bare Metal Coronary Stents
    • 3.3.3 European Market for Absorbable Coronary Stents
  • 3.4 Asia/Pacific Market for Coronary Stents
    • 3.4.1 Asia/Pacific Market for Drug-Eluting Coronary Stents
    • 3.4.2 Asia/Pacific Market for Bare Metal Coronary Stents
    • 3.4.3 Asia/Pacific Market for Absorbable Coronary Stents
  • 3.5 Rest of World (ROW) Market for Coronary Stents
    • 3.5.1 ROW Market for Drug-Eluting Coronary Stents
    • 3.5.2 ROW Market for Bare Metal Coronary Stents
    • 3.5.3 ROW Market for Absorbable Coronary Stents

SECTION 4: COMPANY PROFILES

  • 4.1 Aachen Resonance GmbH
  • 4.2 Abbott Vascular
  • 4.3 AdvanSource Biomaterials Corporation
  • 4.4 Aeon Bioscience
  • 4.5 Allvivo Vascular, Inc.
  • 4.6 Amaranth Medical, Inc.
  • 4.7 amg International GmbH
  • 4.8 Arterial Remodeling Technologies (ART)
  • 4.9 Atrium Medical
  • 4.10 Avantec Vascular
  • 4.11 B. Braun Melsungen
  • 4.12 Balton Ltd.
  • 4.13 Bioabsorbable Therapeutics, Inc.
  • 4.14 Bioring SA
  • 4.15 Biosensors International
  • 4.16 Biotronik
  • 4.17 Blue Medical Devices B.V.
  • 4.18 Boston Scientific
  • 4.19 Caliber Therapeutics
  • 4.20 Cappella Inc.
  • 4.21 CardioMind, Inc.
  • 4.22 CeloNova BioSciences, Inc.
  • 4.23 CID S.r.l. (Formerly Sorin Vascular Therapy)
  • 4.24 Cinvention AG (Formerly Blue Membranes)
  • 4.25 CorNova
  • 4.26 CV Therapeutics/Gilead Inc.
  • 4.27 Devax
  • 4.28 DISA Vascular
  • 4.29 Elixir Medical Corp.
  • 4.30 Estracure Inc.
  • 4.31 eucatech AG
  • 4.32 Genesis Technologies, LLC
  • 4.33 Global Therapeutics (Cook Medical)
  • 4.34 Hexacath
  • 4.35 ICON Interventional (Formerly ICON Medical Corp.)
  • 4.36 InspireMD
  • 4.37 InTek Technology
  • 4.38 Invatec s.r.l.
  • 4.39 ITGI Medical Ltd.
  • 4.40 Johnson & Johnson
    • 4.40.1 Cordis
    • 4.40.2 Conor Medsystems (J&J)
  • 4.41 JW Medical Systems / Biosensors International
  • 4.42 Kaneka Corporation
  • 4.43 Kyoto Medical Planning Co., Ltd.
  • 4.44 Lepu Medical
  • 4.45 Lutonix, Inc.
  • 4.46 Medinol/ARIAD Pharmaceuticals
  • 4.47 Medlogics Device Corporation (MDC)
  • 4.48 Medtronic Vascular
  • 4.49 Miami Cardiovascular Innovations
  • 4.50 Micell Technologies
  • 4.51 MicroPort Scientific Corporation
  • 4.52 Minvasys
  • 4.53 MIV Therapeutics
  • 4.54 mNEMOSCIENCE GmbH
  • 4.55 MoBeta, Inc.
  • 4.56 NanoInterventions, LLC
  • 4.57 Neovasc, Inc.
  • 4.58 Nexeon MedSystems, Inc.
  • 4.59 Opto Circuits (India) Ltd.
    • 4.59.1 EuroCor GmbH
  • 4.60 OrbusNeich
  • 4.61 Palmaz Scientific, Inc.
  • 4.62 Picarus NV
  • 4.63 Possis Medical (Bayer)
  • 4.64 Prescient Medical
  • 4.65 Relisys Medical Devices
  • 4.66 REVA Medical
  • 4.67 Sahajanand Medical Technologies
  • 4.68 Stentys SAS
  • 4.69 Terumo
  • 4.70 Translumina
  • 4.71 TriReme Medical
  • 4.72 Tryton Medical
  • 4.73 Vascular Concepts
  • 4.74 VasoTech, Inc.
  • 4.75 X-Cell Medical
  • 4.76 Xtent, Inc. (ceasing operations)

APPENDIX I: SELECTED CLINICAL TRIALS

  • ABSORB
  • ARRIVE II Registry
  • ARTS
  • AXXESS PLUS
  • BASKET
  • BBC ONE
  • CARE
  • COREL
  • COSTAR
  • COURAGE
  • CUSTOM
  • DEScover Registry
  • DIRECT
  • DIVERGE
  • e-HEALING
  • EASTER Registry
  • ENDEAVOR
  • ETHOS
  • EuroSTAR
  • EVENT Registry
  • FAME
  • GENESIS
  • FOCUS
  • HEALING
  • HORIZONS-AMI
  • ISAR, ISAR-TEST-2
  • LONG DES
  • NOBLESS
  • NOBORI
  • NORDIC
  • OLYMPIA Registry
  • PASSION
  • PREPARE
  • PROGRESS
  • RESOLUTE
  • RESORB
  • REWARD Registries
  • SERIES
  • SIMPLE Registries
  • SIRIUS, E-SIRIUS, C-SIRIUS
  • SORT-OUT III
  • SPIRIT
  • STEALTH
  • STEMI
  • STENT Registry
  • SVELT
  • TAXUS
  • TYPHOON
  • ZEST-AMI
  • ZOMAXX

APPENDIX II: COMPANY DIRECTORY

List of Exhibits
  • Exhibit ES-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
  • Exhibit ES-2: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
  • Exhibit ES-3: Potential Complications Related to Implantation of Cardiovascular Stents
  • Exhibit ES-4: Types of Coronary Stents and Selected Anti-Restenosis Devices
  • Exhibit ES-5: Worldwide DES Market by Company, Calendar 4th Quarter, 2008
  • Exhibit ES-6: Worldwide Market for Coronary Stents, by Type, Revenue Forecast, 2008 - 2017
  • Exhibit ES-7: Worldwide Market for Drug-Eluting Coronary Stents, by Region, Revenue Forecast, 2008 - 2017
  • Exhibit ES-8: Worldwide Market for Bare Metal Coronary Stents, by Region, Revenue Forecast, 2008 - 2017
  • Exhibit ES-9: Worldwide Market for Absorbable Coronary Stents, by Region, Revenue, 2012 - 2017
  • Exhibit 1-1: Types of Cardiovascular Disease and Incidence in the United States, 2006
  • Exhibit 1-2: International Death Rates Per 100,000 Population for Total Cardiovascular Disease and Coronary Heart Disease for the Top 20 Countries
  • Exhibit 1-3: Prevalence, Mortality and Hospital Discharges for Cardiovascular Disease Patients in the United States
  • Exhibit 1-4: Drug-Eluting Balloon Catheters
  • Exhibit 1-5: Estimated Inpatient Cardiovascular Procedures, U.S., 2006 (000)
  • Exhibit 1-6: Number of Discharges, Coronary Atherosclerosis, U.S.
  • Exhibit 1-7: National Healthcare Cost and Utilization Project Statistics: Mean Charges and In-Hospital Death Rates for Various Cardiovascular Procedures, U.S.
  • Exhibit 1-8: Total Number of Cardiac Revascularization Discharges and Mean Charges, U.S., 1993 - 2006
  • Exhibit 1-9: Total Number of Discharges for PCI Procedures with Non-Drug-Eluting Stents and Mean Charges, U.S., 2002 - 2006
  • Exhibit 1-10: Total Number of Discharges for PCI Procedures with Drug-Eluting Stents and Mean Charges, U.S., 2002 - 2006
  • Exhibit 1-11: Total Number of Discharges for PCI Procedures with Non-Drug and Drug-Eluting Stent Discharges and Mean Charges, U.S., 2002 - 2006
  • Exhibit 2-1: Competitors in the Market for Bare Metal Stents
  • Exhibit 2-2: Competitors in the Market for Drug-Eluting Stents
  • Exhibit 2-3: Competitors in the Market for Bioresorbable Stents
  • Exhibit 2-4: Competitors in the Market for Novel Stent Technologies
  • Exhibit 3-1: Worldwide Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-2: Worldwide Drug-Eluting Coronary Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-3: Revenues for Leading Drug-Eluting Stent Market Competitors, Worldwide, 2008
  • Exhibit 3-4: Worldwide Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-5: Worldwide Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
  • Exhibit 3-6: U.S. Market for Coronary Stents, by Type, Revenue Forecast, 2008-2017
  • Exhibit 3-7: U.S. Coronary Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-8: Revenues for Leading Drug-Eluting Stent Market Competitors, United States, 2008
  • Exhibit 3-9: U.S. Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-10: U.S. Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
  • Exhibit 3-11: European Coronary Stent Market, by Type, Revenue Forecast, 2008-2017
  • Exhibit 3-12: European Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-13: European Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-14: European Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2013-2017
  • Exhibit 3-15: Asia/Pacific Market Forecasts for Coronary Stents, by Type, Revenue Forecast, 2008-2017
  • Exhibit 3-16: Asia/Pacific Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-17: Asia/Pacific Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-18: Asia/Pacific Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
  • Exhibit 3-19: Rest of World Coronary Stent Market, by Type, Revenue Forecast 2008-2017
  • Exhibit 3-20: Rest of World Drug-Eluting Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-21: Rest of World Coronary Bare Metal Stent Market, Unit and Revenue Forecast, 2008-2017
  • Exhibit 3-22: Rest of World Coronary Absorbable Stent Market, Unit and Revenue Forecast, 2012-2017
  • Exhibit 4-1: AdvanSource Biomaterials Third Quarter Financial Results ($000s)
  • Exhibit 4-2: Medtronic Financial Data, Third Quarter 2009 ($millions)
  • Exhibit 4-3: Medtronic' s Coronary Stent Revenues, FY 2008 & 2009 ($millions)
  • Exhibit 4-4: Xtent Financial Data, Fourth-Quarter 2008 ($millions)
Back to Top